By Adriano Marchese
Eupraxia Pharmaceuticals has appointed Alex Rothwell to return as its next chief financial officer, effective immediately.
Rothwell brings to the clinical-stage biotechnology company more than 25 years of experience as a business leader and as a senior executive in the Canadian capital markets and investment banking, Eupraxia said Tuesday.
He was Eupraxia's CFO from 2018 to 2021.
Most recently, Rothwell has been a senior advisor to Fort Capital Partners, a Canadian boutique investment bank.
Bruce Cousins, the company's outgoing CFO, is set to retire but will remain as a consultant in the near-term to ensure an orderly transition of responsibilities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 18, 2025 07:16 ET (12:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.